---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-132774"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:30:44.902327+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics reports positive ENLIGHTEN 2 Phase 3 trial: LYR-210 meets primary endpoint in CRS (p=0.0078)

## Summary
- ENLIGHTEN 2 met primary endpoint: LYR-210 improved 3CS composite score vs sham at 24 weeks (-1.13, p=0.0078) in non-polyp patients.
- Key secondary endpoints met in full population: 3CS (p=0.0209) and SNOT-22 (-8.7, p=0.0101) at 24 weeks; SNOT-22 improvement seen from week 4.
- LYR-210 well-tolerated with safety similar to sham; pooled analysis in 64 nasal polyp patients showed positive trends in multiple endpoints.
- Company plans to align with FDA on NDA submission in non-polyp patients and continue development in nasal polyp patients.
- Effective May 27, 2025, company effected a 1-for-50 reverse stock split (ticker unchanged LYRA).

## SEC filing metadata
- accession: 0001193125-25-132774
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000119312525132774/0001193125-25-132774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000119312525132774/d948302d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-132774
- JSON: https://secwatch.observer/filing/0001193125-25-132774.json
- Plain text: https://secwatch.observer/filing/0001193125-25-132774.txt

## Key facts
- Governance Changes
  Lyra Therapeutics, Inc.: Certificate of Amendment to Restated Certificate of Incorporation to effect a 1-for-50 reverse stock split, effective May 27, 2025 at 5:00 p.m. Eastern Time (effective 2025-05-27).
  - Change: charter amendment
  - Effective: 2025-05-27
  source text: On May 27, 2025, Lyra Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended (the “Charter Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), effective May 27, 2025 at 5:00 p.m., Eastern Time (the “Effective Time”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000119312525132774/0001193125-25-132774-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.